News for Healthier Living

Emmecell Completes Last Patient Last Visit for Proof-of-Concept Trial of Groundbreaking Cell Therapy for Corneal Edema

Emmetrope Ophthalmics, LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced the successful completion of the last patient last visit in its phase 1 extension study EMME-001, a 21-patient randomized, double-masked, US based, multi-center trial assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

October 8, 2024


October 19 2024

October 18 2024

October 17 2024

October 16 2024

October 15 2024

October 14 2024

October 13 2024

October 12 2024

October 11 2024

October 10 2024

October 9 2024

October 8 2024

October 7 2024

October 6 2024

October 5 2024